FMR LLC Reports 5.54M Shares (5.4%) of Nurix

FMR LLC reports 5,541,271.11 shares (5.4%) of Nurix Therapeutics common stock as beneficially owned as of 03/31/2026.

Rhea-AI Filing Summary

FMR LLC reports 5,541,271.11 shares (5.4%) of Nurix Therapeutics common stock as beneficially owned as of 03/31/2026. The filing of a Schedule 13G states that FMR LLC holds 5,541,271.11 shares with sole dispositive power and sole voting power reported on the cover. The filing also lists Abigail P. Johnson as having shared attribution to the same 5,541,271.11 shares. The filing notes that one or more other persons may have rights to dividends or sale proceeds but no single outside person holds over 5% individually. Exhibit references and a power of attorney are attached.

Insights

Institutional Ownership Analyst

FMR LLC holds a mid-single-digit stake in Nurix as of 03/31/2026.

FMR LLC's reported 5,541,271.11 shares (5.4%) is a disclosure of beneficial ownership under Schedule 13G, indicating passive investor status rather than an activist position. The sole dispositive power and voting power entries show control over disposition and voting for the reported shares.

Watch subsequent filings for any change to >10% or a switch to Schedule 13D, which would indicate a shift from passive to active intent; timing not specified in the excerpt.

Securities Compliance Counsel

Filing contains standard Schedule 13G disclosures and accompanying exhibits and powers of attorney.

The filing references Exhibit 99 for a 13d-1(k)(1) agreement and incorporates a power of attorney effective April 13, 2026. Signatures by authorized representatives are provided with dates.

From a compliance view, the form lists beneficial ownership and appropriate exhibit cross-references; further due diligence would check Exhibit 99 and Exhibit 24 for delegation details.

Key Figures

Filing type: Schedule 13G Shares beneficially owned: 5,541,271.11 shares Percent of class: 5.4% +2 more

5 metrics

Filing type Schedule 13G Beneficial ownership disclosure

Shares beneficially owned 5,541,271.11 shares as of 03/31/2026

Percent of class 5.4% common stock of Nurix Therapeutics

CUSIP 67080M103 Nurix Therapeutics common stock identifier

Sole voting/dispositive power 5,532,665.00 / 5,541,271.11 voting power / dispositive power reported on cover

Key Terms

Schedule 13G, Beneficial ownership, Sole dispositive power

3 terms

Schedule 13G regulatory

"Item 1. Name of issuer: NURIX THERAPEUTICS INC"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficial ownership financial

"Item 4. Ownership (a) Amount beneficially owned: 5541271.11"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole dispositive power regulatory

"Item 4. (iii) Sole power to dispose: 5541271.11"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does FMR LLC report in Nurix Therapeutics (NRIX)?

FMR LLC reports 5,541,271.11 shares, equal to 5.4% of common stock as beneficially owned as of 03/31/2026. The amount is shown with sole dispositive and sole voting power on the Schedule 13G cover page.

Does the Schedule 13G indicate active control or passive investment by FMR LLC?

The filing is a Schedule 13G disclosure, consistent with a passive investor classification. It reports beneficial ownership and voting/dispositive powers but does not state an intent to influence control or an activist purpose.

How is Abigail P. Johnson listed in the filing for NRIX?

Abigail P. Johnson is listed with 5,541,271.11 shares of common stock attributed and the same 5.4% figure; the filing shows her citizenship and a signature line tied to the power of attorney used to sign on behalf of FMR LLC.

Are there other parties with rights to dividends or sale proceeds?

The filing states one or more other persons may have the right to dividends or proceeds, but it also states no single other person is known to hold more than 5% of the outstanding common stock.

Where can I find supporting agreements and authorization details in the filing?

The Schedule 13G references Exhibit 99 for a 13d-1(k)(1) agreement and incorporates a power of attorney by reference to Exhibit 24; those exhibits contain the supporting authorization and delegation details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 11:30 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

NURIX THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

67080M103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 67080M103

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,532,665.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,541,271.11
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,541,271.11

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 67080M103

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,541,271.11
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,541,271.11

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NURIX THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 1600 SIERRA POINT PKWY,BRISBANE,CA,USA,94005
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 67080M103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5541271.11
(b)	Percent of class: 5.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 5541271.11
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of NURIX THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of NURIX THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	05/05/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	05/05/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.